OA10909A - Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone) its preparation and its use as dopamine d2 antagonist - Google Patents

Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone) its preparation and its use as dopamine d2 antagonist Download PDF

Info

Publication number
OA10909A
OA10909A OA9800206A OA9800206A OA10909A OA 10909 A OA10909 A OA 10909A OA 9800206 A OA9800206 A OA 9800206A OA 9800206 A OA9800206 A OA 9800206A OA 10909 A OA10909 A OA 10909A
Authority
OA
OAPI
Prior art keywords
ziprasidone
indol
dihydro
benzisothiazol
piperazinyl
Prior art date
Application number
OA9800206A
Other languages
English (en)
French (fr)
Inventor
Frank Robert Busch
Carol Anne Rose
Russell James Shine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA10909A publication Critical patent/OA10909A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
OA9800206A 1996-05-07 1998-10-30 Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone) its preparation and its use as dopamine d2 antagonist OA10909A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
OA10909A true OA10909A (en) 2001-10-26

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800206A OA10909A (en) 1996-05-07 1998-10-30 Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone) its preparation and its use as dopamine d2 antagonist

Country Status (41)

Country Link
US (1) US6245765B1 (sk)
EP (1) EP0918772B1 (sk)
JP (1) JP3494659B2 (sk)
KR (1) KR100333215B1 (sk)
CN (1) CN1091769C (sk)
AP (1) AP765A (sk)
AR (1) AR007004A1 (sk)
AT (1) ATE278689T1 (sk)
AU (1) AU731267B2 (sk)
BG (1) BG63544B1 (sk)
BR (1) BR9709889A (sk)
CA (1) CA2252898C (sk)
CO (1) CO4940466A1 (sk)
CZ (1) CZ289215B6 (sk)
DE (1) DE69731094T2 (sk)
DK (1) DK0918772T3 (sk)
DZ (1) DZ2222A1 (sk)
EA (1) EA001190B1 (sk)
EG (1) EG24076A (sk)
ES (1) ES2229342T3 (sk)
GT (1) GT199700052A (sk)
HK (1) HK1017892A1 (sk)
HR (1) HRP970236B1 (sk)
ID (1) ID16867A (sk)
IL (1) IL126591A (sk)
IS (1) IS2080B (sk)
MA (1) MA24171A1 (sk)
MY (1) MY119997A (sk)
NO (1) NO312514B1 (sk)
NZ (1) NZ332218A (sk)
OA (1) OA10909A (sk)
PL (1) PL188330B1 (sk)
PT (1) PT918772E (sk)
SI (1) SI0918772T1 (sk)
SK (1) SK282837B6 (sk)
TN (1) TNSN97074A1 (sk)
TR (1) TR199802240T2 (sk)
TW (1) TW491847B (sk)
UA (1) UA46840C2 (sk)
WO (1) WO1997042191A1 (sk)
ZA (1) ZA973876B (sk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EE200200670A (et) * 2000-06-02 2004-08-16 Pfizer Products Inc. S-metüüldihüdroziprasidoon psühhiaatriliste ja silmahaiguste raviks
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
WO2005016325A2 (en) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
BRPI0518187A (pt) * 2004-11-16 2008-11-04 Elan Pharma Int Ltd formulações de olanzapina em nanopartìcula injetáveis
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
EP1742943A1 (en) * 2005-02-11 2007-01-17 Teva Pharmaceutical Industries Ltd Process of preparing ziprasidone mesylate
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
JP2010527925A (ja) * 2007-05-18 2010-08-19 サイドース・エルエルシー ジプラシドン製剤
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
US9469630B2 (en) * 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
SI0904273T1 (en) 1996-05-07 2003-08-31 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Also Published As

Publication number Publication date
AP765A (en) 1999-09-17
GT199700052A (es) 2001-08-29
AU2174797A (en) 1997-11-26
NO985194L (no) 1998-11-06
AR007004A1 (es) 1999-10-13
AP9700976A0 (en) 1997-07-31
EP0918772B1 (en) 2004-10-06
IL126591A (en) 2001-11-25
JP3494659B2 (ja) 2004-02-09
EG24076A (en) 2008-05-11
BG102892A (en) 1999-09-30
DK0918772T3 (da) 2005-01-10
DE69731094T2 (de) 2006-02-23
NO312514B1 (no) 2002-05-21
ES2229342T3 (es) 2005-04-16
CZ289215B6 (cs) 2001-12-12
CA2252898C (en) 2003-04-08
TNSN97074A1 (fr) 2005-03-15
ZA973876B (en) 1998-11-06
EP0918772A1 (en) 1999-06-02
IS4874A (is) 1998-10-20
HK1017892A1 (en) 1999-12-03
NO985194D0 (no) 1998-11-06
JPH11509867A (ja) 1999-08-31
PT918772E (pt) 2004-12-31
US6245765B1 (en) 2001-06-12
SK282837B6 (sk) 2002-12-03
CO4940466A1 (es) 2000-07-24
HRP970236A2 (en) 1998-06-30
UA46840C2 (uk) 2002-06-17
SI0918772T1 (en) 2005-02-28
PL188330B1 (pl) 2005-01-31
MA24171A1 (fr) 1997-12-31
BG63544B1 (bg) 2002-04-30
DZ2222A1 (fr) 2002-12-03
CA2252898A1 (en) 1997-11-13
CN1216991A (zh) 1999-05-19
KR100333215B1 (ko) 2002-06-20
WO1997042191A1 (en) 1997-11-13
IL126591A0 (en) 1999-08-17
MY119997A (en) 2005-08-30
EA001190B1 (ru) 2000-12-25
TW491847B (en) 2002-06-21
CN1091769C (zh) 2002-10-02
ATE278689T1 (de) 2004-10-15
HRP970236B1 (en) 2002-12-31
NZ332218A (en) 2005-02-25
BR9709889A (pt) 1999-08-10
PL329884A1 (en) 1999-04-12
IS2080B (is) 2006-02-15
DE69731094D1 (de) 2004-11-11
CZ349398A3 (cs) 1999-09-15
AU731267B2 (en) 2001-03-29
ID16867A (id) 1997-11-20
SK150898A3 (en) 2000-02-14
EA199800912A1 (ru) 1999-04-29
KR20000010824A (ko) 2000-02-25
TR199802240T2 (sk) 1999-02-22

Similar Documents

Publication Publication Date Title
OA10909A (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone) its preparation and its use as dopamine d2 antagonist
AP838A (en) Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one.
NZ508304A (en) Mesylate dihydrate salt of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ( ziprasidone) useful as dopamine D2 antagonist
JP2022552329A (ja) 化合物の塩及びその結晶形態
MXPA98009242A (en) Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2-